Posters
Recombinant Human Growth Hormone Therapy Clinical Outcomes at an Integrated Health System Specialty Pharmacy
This study assess the impact of a health system specialty pharmacy program on operational and clinical outcomes for patients on hGH.
Insights
Integrated Specialty Care
Posters
This study assess the impact of a health system specialty pharmacy program on operational and clinical outcomes for patients on hGH.
Posters
This poster explores the ability of integrated health system specialty pharmacies to mitigate barriers faced by patients taking Glucagon-like peptide-1 receptor agonists (GLP-1 RAs).
Articles
Improve specialty outcomes and access to therapy with Shields’ platform that combines embedded clinical expertise with AI-enabled automation and intelligent workflows to drive connected performance.
Articles
Starting January 1, 2027, the 340B landscape may shift following the Health Resources and Services Administration’s (HRSA) implementation of the revised 340B Rebate Model Pilot Program (“Pilot Program
Posters
Mavacamten is a first in class myosin inhibitor used in the treatment of obstructive hypertrophic cardiomyopathy (oHCM).
Posters
Case Studies
When care teams work in sync, patients with bleeding disorders see real results.
Articles
White Papers
Discover how a pharmacist-led telehealth diabetes support program delivered results for health systems and the patients that conventional care couldn't reach.
Articles
Articles
Articles
The 5th Annual Shields Specialty Pharmacy Outcomes Report is here. Featuring results from more than 2 million patients across 50+ integrated disease states and nearly 80 health system partners.
Turn insight into impact with a partner that delivers proven results for health systems and patients.